Related references
Note: Only part of the references are listed.B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Richard A. Furie et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis
Edward Fox et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
Systematic review of safety and efficacy of belimumab in treating immune-mediated disorders
Celine Kaegi et al.
ALLERGY (2021)
Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab
Lionel Rouge et al.
SCIENCE (2020)
Successful Treatment of Patients With Refractory PLA2R-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases
Nattawat Klomjit et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases
Lars Fugger et al.
CELL (2020)
Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders
Celine Kaegi et al.
FRONTIERS IN IMMUNOLOGY (2020)
Five years of ocrelizumab in relapsing multiple sclerosis OPERA studies open-label extension
Stephen L. Hauser et al.
NEUROLOGY (2020)
Ofatumumab versus Teriflunomide in Multiple Sclerosis
Stephen L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Binding mechanisms of therapeutic antibodies to human CD20
Anand Kumar et al.
SCIENCE (2020)
Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis
H-P Hartung et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Accelerating the Depletion of Circulating Anti-Phospholipase A2 Receptor Antibodies in Patients with Severe Membranous Nephropathy: Preliminary Findings with Double Filtration Plasmapheresis and Ofatumumab
Manuel Alfredo Podesta et al.
NEPHRON (2020)
A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder
Maureen A. Mealy et al.
MEDICINE (2019)
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Celine Kaegi et al.
FRONTIERS IN IMMUNOLOGY (2019)
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis The MIRROR study
Amit Bar-Or et al.
NEUROLOGY (2018)
Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis
Ivan Jelcic et al.
CELL (2018)
A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
Kensei Tobinai et al.
ADVANCES IN THERAPY (2017)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples
Venkat Reddy et al.
RHEUMATOLOGY (2017)
Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long-Term Effects on Serum Immunoglobulins
Venkat Reddy et al.
ARTHRITIS CARE & RESEARCH (2017)
Therapeutic Antibodies: What Have we Learnt from Targeting CD20 and Where Are We Going?
Michael J. E. Marshall et al.
FRONTIERS IN IMMUNOLOGY (2017)
Immune regulation by glucocorticoids
Derek W. Cain et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?
Venkat Reddy et al.
DRUG DISCOVERY TODAY (2016)
Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia
Howard A. Liebman et al.
HAEMATOLOGICA (2016)
Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series
Stephen P. McAdoo et al.
RHEUMATOLOGY (2016)
Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia
Howard A. Liebman et al.
HAEMATOLOGICA (2016)
Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials
Emilia Quattrocchi et al.
PLOS ONE (2016)
Ofatumumab treatment in lupus nephritis patients
Malena Loberg Haarhaus et al.
CLINICAL KIDNEY JOURNAL (2016)
EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders
O. Boyman et al.
ALLERGY (2015)
Antibody-independent functions of B cells: a focus on cytokines
Ping Shen et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Adverse reactions to biologic agents and their medical management
Onur Boyman et al.
NATURE REVIEWS RHEUMATOLOGY (2014)
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis A phase 2 study
Per S. Sorensen et al.
NEUROLOGY (2014)
Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study
Eduardo F. Mysler et al.
ARTHRITIS AND RHEUMATISM (2013)
Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study
Howard A. Liebman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
B-cell biology and development
Kathrin Pieper et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Subcutaneously Administered Ofatumumab in Rheumatoid Arthritis: A Phase I/II Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics
Regina Kurrasch et al.
JOURNAL OF RHEUMATOLOGY (2013)
Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjogren's syndrome after B cell depletion therapy
Nishath Hamza et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial
William Stohl et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial
P. P. Tak et al.
ARTHRITIS AND RHEUMATISM (2012)
Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial
W. Rigby et al.
ARTHRITIS AND RHEUMATISM (2012)
Safety and Efficacy of Various Dosages of Ocrelizumab in Japanese Patients with Rheumatoid Arthritis with an Inadequate Response to Methotrexate Therapy: A Placebo-controlled Double-blind Parallel-group Study
Masayoshi Harigai et al.
JOURNAL OF RHEUMATOLOGY (2012)
Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial
Peter C. Taylor et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Ludwig Kappos et al.
LANCET (2011)
Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, for Treatment of Rheumatoid Arthritis With an Inadequate Response to One or More Disease-Modifying Antirheumatic Drugs Results of a Randomized, Double-Blind, Placebo-Controlled, Phase I/II Study
Mikkel Ostergaard et al.
ARTHRITIS AND RHEUMATISM (2010)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
B-cell targeted therapies in human autoimmune diseases: an updated perspective
Michael J. Townsend et al.
IMMUNOLOGICAL REVIEWS (2010)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Skin cancer in organ transplant recipients -: Where do we stand today?
C. Ulrich et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2008)
Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis - A phase I/II randomized, blinded, placebo-controlled, dose-ranging study
Mark C. Genovese et al.
ARTHRITIS AND RHEUMATISM (2008)
Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling
Claire A. Walshe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
JCW Edwards et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
